Developer docs
API playgroundTry for free, no card

Search company profiles

IRIDEX

Full company profile

uuid000493w

Namestring
IRIDEX
Legal namestring
Iridex Corporation
Websiteurl
iridex.com
Company typeenum
Public
Founded yearint
1989
Descriptiontext

IRIDEX Corporation, founded in 1989 and listed on NASDAQ under ticker IRIX, develops and manufactures laser-based medical systems for ophthalmic applications, serving ophthalmologists, retina specialists, glaucoma specialists, and veterinary ophthalmologists across hospitals, ambulatory surgery centers, and office-based practices. Its product portfolio is anchored by the proprietary MicroPulse tissue-sparing laser technology, protected by a European patent granted February 2024, and centers on two therapeutic franchises: Glaucoma (Cyclo G6 810nm infrared laser, MicroPulse P3 device, G-Probe, G-Probe Illuminate, MLT lens) and Retina (IQ 532, IQ 577, OcuLight, and the PASCAL platform with Synthesis, TwinStar, and LIO variants), complemented by EndoProbe handpieces and TxCell scanning delivery systems. The MicroPulse platform enables repeatable, fovea-friendly treatments that reduce collateral tissue damage versus continuous-wave lasers, with a five-year clinical study and independent Maastricht retreatment data supporting efficacy claims.

The company generates revenue through a mix of one-time capital equipment sales of laser consoles and a recurring stream of single-use consumables such as G-Probe devices (CPT code 66710, reimbursed at $453 in physician office and $836 in ASC facility settings), plus service and support. IRIDEX distributes through a U.S. direct field sales force, a wholly-owned European subsidiary (Iridex Europe GmbH in Mannheim), over 100 international distributors covering 60+ countries, and the EyeProGPO group purchasing organization partnership that reaches 1,800+ member practices. Under CEO Patrick Mercer (appointed October 2024), IRIDEX achieved positive adjusted EBITDA in Q4 2025 on 16% quarterly revenue growth and an 8% full-year revenue gain to $52.7M, while restructuring operations including a 2026 headquarters relocation from Mountain View to San Jose and the transition to third-party manufacturing to capture $0.4M-$0.6M in annual cost savings.

Short descriptiontext

IRIDEX Corporation develops and manufactures proprietary MicroPulse laser systems for ophthalmology, serving ophthalmologists and retina/glaucoma specialists in hospitals, ASCs, and practices across 60+ countries. It generates revenue from capital laser consoles and recurring single-use consumables.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic laser systems, medical device manufacturing, retinal disease treatment, glaucoma laser therapy, ophthalmology equipment
Industry2 codes
PRIMARYHLAHAJAI
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAJ
Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Ophthalmic Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Laser Systems (Capital Equipment)
TypeOne Time License
Description

Sale of laser console systems including Cyclo G6, IQ 532, IQ 577, OcuLight, and PASCAL platforms. These are capital equipment purchases by hospitals, ASCs, and physician practices.

iridex.com
2Consumables and Delivery Devices
TypeHardware Sales
Description

Recurring revenue from single-use consumables including G-Probe devices (sold in boxes of 6), glaucoma probes, laser probes, and other disposable delivery devices used during procedures.

iridex.com
3Service and Support
TypeProfessional Services
Description

Technical and customer support services for installed base of laser systems.

iridex.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1G-Probe single-use delivery device
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Part number 15980, sold in boxes of 6 probes. Single-use device with 3-year shelf life.

iridex.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1PASCAL
Description

PASCAL (Patterned Scanning Laser) laser platform for retina treatments, including PASCAL Synthesis and PASCAL TwinStar systems

iridex.com
+7 more records
Core offering1 text field

IRIDEX develops, manufactures, and markets laser-based medical systems and single-use delivery devices used by ophthalmologists, retina specialists, and glaucoma specialists to treat retinal diseases (including diabetic macular edema, age-related macular degeneration, and central serous chorioretinopathy) and glaucoma. Its core platforms are the Cyclo G6, IQ 532, IQ 577, OcuLight, and PASCAL laser systems, along with proprietary MicroPulse tissue-sparing technology and consumable delivery devices such as the G-Probe, G-Probe Illuminate, and MicroPulse P3. Revenue is generated through capital equipment sales to hospitals, ambulatory surgery centers, and physician offices, recurring consumable purchases, and service and support contracts.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Intraocular pressure reductions of 25-35% in glaucoma patients using MicroPulse transscleral laser treatment
+3 more records
Product overview1 text field

IRIDEX is a medical laser systems company developing and manufacturing laser-based products for ophthalmology treatments. The product portfolio centers on two therapeutic areas: Glaucoma and Retina. Core glaucoma products include the Cyclo G6 laser system (810 nm infrared), MicroPulse P3 device, G-Probe and G-Probe Illuminate for transscleral cyclophotocoagulation, and MLT lens for laser trabeculoplasty. Retina products include the IQ 532 (green, 532 nm) and IQ 577 (yellow, 577 nm) laser systems, OcuLight lasers, and the PASCAL laser platform with Synthesis, TwinStar, and LIO variants. The proprietary MicroPulse technology platform enables tissue-sparing treatments by delivering laser energy in repetitive pulses. Products are sold through direct sales and distributor networks in over 60 countries. Accessories include EndoProbe handpieces, TxCell scanning delivery system, LIO devices, and veterinary/ENT products.

Product and service15 records
1Cyclo G6 Laser System
CategoryGlaucoma Laser Systems
Description

810 nm infrared laser system for glaucoma treatment that can operate in both MicroPulse mode and continuous-wave mode for transscleral cyclophotocoagulation (TSCPC). Available in more than 60 countries.

2IQ 532 Laser
CategoryRetinal Laser Systems
Description

532 nm green wavelength laser system for retinal treatments, delivering high power up to 2500 mW with pulse durations from 100 to 3000 ms, available with MicroPulse technology for fovea-friendly treatments.

3IQ 577 Laser
CategoryRetinal Laser Systems
Description

577 nm yellow wavelength laser preferred by retina surgeons for peak absorption in oxygenated hemoglobin tissues, available with MicroPulse technology for fovea-friendly retinal treatments.

4OcuLight Laser System
CategoryRetinal Laser Systems
Description

Diode laser systems for ophthalmic applications including SL, SLx, GL, GLx, and TX variants for retinal photocoagulation treatments.

5PASCAL Laser Platform
CategoryRetinal Laser Systems
Description

Gold standard patterned scanning laser platform for retina treatments featuring a patented 4-fiber design for high-volume efficiency; now available with MicroPulse technology integration. Includes PASCAL Synthesis, PASCAL TwinStar, and PASCAL LIO variants.

6G-Probe Delivery Device
CategoryGlaucoma Consumables
Description

Single-use delivery device for continuous-wave transscleral cyclophotocoagulation (CW-TSCPC) to lower intraocular pressure by selective ablation of ciliary processes; validated for single use only with 3-year shelf life and sold in boxes of 6 (part number 15980).

7G-Probe Illuminate
CategoryGlaucoma Consumables
Description

Enhanced G-Probe variant with integrated illumination for improved visualization during transscleral cyclophotocoagulation procedures.

8MicroPulse P3 Device
CategoryGlaucoma Consumables
Description

Delivery device enabling MicroPulse transscleral laser treatment using the Cyclo G6 laser system for glaucoma management with tissue-sparing benefits.

9MicroPulse Laser Trabeculoplasty (MLT) Lens
CategoryGlaucoma Consumables
Description

Specialized contact lens for MicroPulse laser trabeculoplasty procedures in glaucoma treatment.

10EndoProbe Handpieces
CategoryRetinal Surgical Instruments
Description

Family of laser delivery handpieces for vitreoretinal surgery, providing precise energy delivery with optional MicroPulse compatibility for tissue-sparing treatments in operating room settings.

11TxCell Scanning Laser Delivery System
CategoryRetinal Delivery Devices
Description

Multi-spot pattern scanning system compatible with IQ 532 and IQ 577 lasers, enabling efficient retinal photocoagulation with confluent patterns for tissue-sparing MicroPulse protocols.

12LIO (Laser Indirect Ophthalmoscope)
CategoryRetinal Delivery Devices
Description

Delivery device for indirect laser delivery through the pupil for retinal treatments, compatible with various Iridex laser systems.

13Veterinary Laser Products
CategoryVeterinary Ophthalmology
Description

Laser systems and accessories designed for veterinary ophthalmology applications for treating animal eye conditions.

14ENT Laser Products
CategoryENT Surgical Lasers
Description

Laser systems designed for ear, nose, and throat surgical applications.

15Vexio Cart
CategoryLaser Accessories
Description

Mobile cart system for transporting and positioning Iridex laser systems in clinical settings.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-07
Description

Partnership with ophthalmology-focused group purchasing organization to provide preferred pricing on IRIDEX retina laser technology to EyeProGPO's 1,800+ member practices, ambulatory surgery centers, and hospitals across the United States. The agreement expands an existing relationship that already included IRIDEX's Cyclo G6 laser and glaucoma probes by adding the PASCAL laser platform, IQ 532 and IQ 577 lasers, and OcuLight TX laser. CEO Patrick Mercer stated the on-contract status reinforces technology credibility and streamlines the sales process while delivering clinical and economic value to retina specialists.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IRIDEX

Ophthalmic Medical Devicesiridex.com

IRIDEX Corporation develops and manufactures proprietary MicroPulse laser systems for ophthalmology, serving ophthalmologists and retina/glaucoma specialists in hospitals, ASCs, and practices across 60+ countries. It generates revenue from capital laser consoles and recurring single-use consumables.

What IRIDEX does

IRIDEX Corporation, founded in 1989 and listed on NASDAQ under ticker IRIX, develops and manufactures laser-based medical systems for ophthalmic applications, serving ophthalmologists, retina specialists, glaucoma specialists, and veterinary ophthalmologists across hospitals, ambulatory surgery centers, and office-based practices. Its product portfolio is anchored by the proprietary MicroPulse tissue-sparing laser technology, protected by a European patent granted February 2024, and centers on two therapeutic franchises: Glaucoma (Cyclo G6 810nm infrared laser, MicroPulse P3 device, G-Probe, G-Probe Illuminate, MLT lens) and Retina (IQ 532, IQ 577, OcuLight, and the PASCAL platform with Synthesis, TwinStar, and LIO variants), complemented by EndoProbe handpieces and TxCell scanning delivery systems. The MicroPulse platform enables repeatable, fovea-friendly treatments that reduce collateral tissue damage versus continuous-wave lasers, with a five-year clinical study and independent Maastricht retreatment data supporting efficacy claims.

The company generates revenue through a mix of one-time capital equipment sales of laser consoles and a recurring stream of single-use consumables such as G-Probe devices (CPT code 66710, reimbursed at $453 in physician office and $836 in ASC facility settings), plus service and support. IRIDEX distributes through a U.S. direct field sales force, a wholly-owned European subsidiary (Iridex Europe GmbH in Mannheim), over 100 international distributors covering 60+ countries, and the EyeProGPO group purchasing organization partnership that reaches 1,800+ member practices. Under CEO Patrick Mercer (appointed October 2024), IRIDEX achieved positive adjusted EBITDA in Q4 2025 on 16% quarterly revenue growth and an 8% full-year revenue gain to $52.7M, while restructuring operations including a 2026 headquarters relocation from Mountain View to San Jose and the transition to third-party manufacturing to capture $0.4M-$0.6M in annual cost savings.

IRIDEX firmographics

Firmographics
Name
IRIDEX
Legal name
Iridex Corporation
Website
https://iridex.com
Company type
Public
Founded year
1989
Operating status
Operating
Headcount range
101–250 employees
Short description
IRIDEX Corporation develops and manufactures proprietary MicroPulse laser systems for ophthalmology, serving ophthalmologists and retina/glaucoma specialists in hospitals, ASCs, and practices across 60+ countries. It generates revenue from capital laser consoles and recurring single-use consumables.
Ownership category
akta.pro rank

IRIDEX industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAJAI
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAJ
Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Ophthalmic laser systems
  • Medical device manufacturing
  • Retinal disease treatment
  • Glaucoma laser therapy
  • Ophthalmology equipment

Where IRIDEX is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices3 records

Markets served

IRIDEX business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Laser Systems (Capital Equipment): Sale of laser console systems including Cyclo G6, IQ 532, IQ 577, OcuLight, and PASCAL platforms. These are capital equipment purchases by hospitals, ASCs, and physician practices.
  2. Consumables and Delivery Devices: Recurring revenue from single-use consumables including G-Probe devices (sold in boxes of 6), glaucoma probes, laser probes, and other disposable delivery devices used during procedures.
  3. Service and Support: Technical and customer support services for installed base of laser systems.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goG-Probe single-use delivery device

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

IRIDEX product offering

Product offering

Core offering

IRIDEX develops, manufactures, and markets laser-based medical systems and single-use delivery devices used by ophthalmologists, retina specialists, and glaucoma specialists to treat retinal diseases (including diabetic macular edema, age-related macular degeneration, and central serous chorioretinopathy) and glaucoma. Its core platforms are the Cyclo G6, IQ 532, IQ 577, OcuLight, and PASCAL laser systems, along with proprietary MicroPulse tissue-sparing technology and consumable delivery devices such as the G-Probe, G-Probe Illuminate, and MicroPulse P3. Revenue is generated through capital equipment sales to hospitals, ambulatory surgery centers, and physician offices, recurring consumable purchases, and service and support contracts.

Product overview

IRIDEX is a medical laser systems company developing and manufacturing laser-based products for ophthalmology treatments. The product portfolio centers on two therapeutic areas: Glaucoma and Retina. Core glaucoma products include the Cyclo G6 laser system (810 nm infrared), MicroPulse P3 device, G-Probe and G-Probe Illuminate for transscleral cyclophotocoagulation, and MLT lens for laser trabeculoplasty. Retina products include the IQ 532 (green, 532 nm) and IQ 577 (yellow, 577 nm) laser systems, OcuLight lasers, and the PASCAL laser platform with Synthesis, TwinStar, and LIO variants. The proprietary MicroPulse technology platform enables tissue-sparing treatments by delivering laser energy in repetitive pulses. Products are sold through direct sales and distributor networks in over 60 countries. Accessories include EndoProbe handpieces, TxCell scanning delivery system, LIO devices, and veterinary/ENT products.

Differentiator

Problem solved

Functional benefit

Brands

  • PASCAL: PASCAL (Patterned Scanning Laser) laser platform for retina treatments, including PASCAL Synthesis and PASCAL TwinStar systems
  • MicroPulse
  • Cyclo G6
  • IQ Lasers
  • EndoProbe
  • TxCell
  • G-Probe
  • OcuLight

Products and services

  • Cyclo G6 Laser System 810 nm infrared laser system for glaucoma treatment that can operate in both MicroPulse mode and continuous-wave mode for transscleral cyclophotocoagulation (TSCPC). Available in more than 60 countries.
  • IQ 532 Laser 532 nm green wavelength laser system for retinal treatments, delivering high power up to 2500 mW with pulse durations from 100 to 3000 ms, available with MicroPulse technology for fovea-friendly treatments.
  • IQ 577 Laser 577 nm yellow wavelength laser preferred by retina surgeons for peak absorption in oxygenated hemoglobin tissues, available with MicroPulse technology for fovea-friendly retinal treatments.
  • OcuLight Laser System Diode laser systems for ophthalmic applications including SL, SLx, GL, GLx, and TX variants for retinal photocoagulation treatments.
  • PASCAL Laser Platform Gold standard patterned scanning laser platform for retina treatments featuring a patented 4-fiber design for high-volume efficiency; now available with MicroPulse technology integration. Includes PASCAL Synthesis, PASCAL TwinStar, and PASCAL LIO variants.
  • G-Probe Delivery Device Single-use delivery device for continuous-wave transscleral cyclophotocoagulation (CW-TSCPC) to lower intraocular pressure by selective ablation of ciliary processes; validated for single use only with 3-year shelf life and sold in boxes of 6 (part number 15980).
  • G-Probe Illuminate Enhanced G-Probe variant with integrated illumination for improved visualization during transscleral cyclophotocoagulation procedures.
  • MicroPulse P3 Device Delivery device enabling MicroPulse transscleral laser treatment using the Cyclo G6 laser system for glaucoma management with tissue-sparing benefits.
  • MicroPulse Laser Trabeculoplasty (MLT) Lens Specialized contact lens for MicroPulse laser trabeculoplasty procedures in glaucoma treatment.
  • EndoProbe Handpieces Family of laser delivery handpieces for vitreoretinal surgery, providing precise energy delivery with optional MicroPulse compatibility for tissue-sparing treatments in operating room settings.
  • TxCell Scanning Laser Delivery System Multi-spot pattern scanning system compatible with IQ 532 and IQ 577 lasers, enabling efficient retinal photocoagulation with confluent patterns for tissue-sparing MicroPulse protocols.
  • LIO (Laser Indirect Ophthalmoscope) Delivery device for indirect laser delivery through the pupil for retinal treatments, compatible with various Iridex laser systems.
  • Veterinary Laser Products Laser systems and accessories designed for veterinary ophthalmology applications for treating animal eye conditions.
  • ENT Laser Products Laser systems designed for ear, nose, and throat surgical applications.
  • Vexio Cart Mobile cart system for transporting and positioning Iridex laser systems in clinical settings.

Quantifiable outcome

  • Intraocular pressure reductions of 25-35% in glaucoma patients using MicroPulse transscleral laser treatment
  • +3 more outcomes

Companies that use IRIDEX

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

IRIDEX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

IRIDEX partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • EyeProGPOcoreChannel Partner/ Reseller/ Distributor · 7 April 2026Partnership with ophthalmology-focused group purchasing organization to provide preferred pricing on IRIDEX retina laser technology to EyeProGPO's 1,800+ member practices, ambulatory surgery centers, and hospitals across the United States. The agreement expands an existing relationship that already included IRIDEX's Cyclo G6 laser and glaucoma probes by adding the PASCAL laser platform, IQ 532 and IQ 577 lasers, and OcuLight TX laser. CEO Patrick Mercer stated the on-contract status reinforces technology credibility and streamlines the sales process while delivering clinical and economic value to retina specialists.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

IRIDEX competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

IRIDEX social profiles

Digital presence

IRIDEX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IRIDEX leadership team

Management profile

Number of profiles

Profiles3 records

IRIDEX subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

IRIDEX funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IRIDEX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IRIDEX

What does IRIDEX do?

IRIDEX develops, manufactures, and markets laser-based medical systems and single-use delivery devices used by ophthalmologists, retina specialists, and glaucoma specialists to treat retinal diseases (including diabetic macular edema, age-related macular degeneration, and central serous chorioretinopathy) and glaucoma. Its core platforms are the Cyclo G6, IQ 532, IQ 577, OcuLight, and PASCAL laser systems, along with proprietary MicroPulse tissue-sparing technology and consumable delivery devices such as the G-Probe, G-Probe Illuminate, and MicroPulse P3. Revenue is generated through capital equipment sales to hospitals, ambulatory surgery centers, and physician offices, recurring consumable purchases, and service and support contracts.

Is IRIDEX a public or private company?

IRIDEX is a public company. It is classified as public and is currently operating.

When was IRIDEX founded?

IRIDEX was founded in 1989. It employs 101 to 250 people.

Where is IRIDEX based?

IRIDEX is headquartered in Mountain View, United States, in the North America region.

How does IRIDEX make money?

Three revenue lines are on record. Laser Systems (Capital Equipment) is the primary driver. The others are consumables and Delivery Devices and service and Support.

Does IRIDEX have an API?

No public API is recorded for IRIDEX.

What industry is IRIDEX in?

IRIDEX's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty), with a secondary code of HLAHAJAJ, Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Motley FoolIRIDEX (IRIX) Q3 2026 Earnings Call TranscriptIRIDEX reported Q3 2026 revenue of $10.2 million, down 19% year-over-year, with gross margin rising to 42.4%. The company lowered its full-year 2026 revenue guidance to $46–48 million, citing international retina challenges and regulatory delays. Management expects 2027 to be more profitable after completing manufacturing relocation and contract manufacturing.The Motley FoolIRIDEX (IRIX) Q3 2026 Earnings Call TranscriptIRIDEX reported Q3 2026 revenue of $10.2 million, down 19% year-over-year, with gross margin rising to 42.4%. The company lowered its full-year 2026 revenue guidance to $46–48 million, citing international retina challenges and regulatory delays. Management expects 2027 to be more profitable after completing manufacturing relocation and transitioning to contract manufacturers.Seeking AlphaIridex anticipates $46M-$48M 2026 revenue as it targets 2027 profitability through San Jose move and portfolio reviewIRIDEX reported Q3 2026 revenue of $10.2 million, down from prior expectations, with a gross margin of 42.4%. Management lowered full-year 2026 revenue guidance to $46-48 million, excluding the Middle East, and cited international retina delays and China weakness. The company targets 2027 profitability through cost cuts and a portfolio review.Investing.comEarnings call transcript: IRIDEX Q3 2026 misses estimates as shares sink 25%IRIDEX reported a Q3 2026 adjusted loss of $0.08 per share and revenue of $10.2 million, missing estimates. The company cut its full-year revenue guidance to $46–48 million, and shares fell 25% in after-hours trading. Management expects 2027 to be more profitable with improved margins.Quiver QuantitativeIRIDEX (IRIX) Stock Falls on Q3 2026 Earnings | IRIX Stock NewsIRIDEX Corp. reported Q3 2026 revenue of $10.2 million, down 18.65% year over year and below the $12.9 million estimate, with a net loss of $1.4 million. The stock fell 31.97% after market close. Gross profit rose 7.2% to $4.3 million, while cash used in operations was $942,000.YahooIridex: Q3 Earnings SnapshotIridex Corp. reported a third-quarter loss of $1.4 million, or 8 cents per share, with revenue of $10.2 million. The medical laser company expects full-year revenue between $46 million and $48 million.Investing.comIridex CFO Romeo Dizon buys $4,977 in company stockRomeo Dizon, CFO of IRIDEX Corp., bought 7,900 shares at $0.63 each on September 16, 2026, totaling $4,977. The purchase follows Q2 2026 results showing a 7-cent loss and $12.6M revenue, below the $14.13M estimate. The company reported positive operating cash flow for the first time.American Banking and Market NewsCritical Analysis: Insulet (NASDAQ:PODD) and IRIDEX (NASDAQ:IRIX)IRIDEX and Insulet are compared on valuation, profitability, and analyst ratings. Insulet beats IRIDEX on 11 of 14 factors, including revenue and earnings, but IRIDEX has a lower P/E ratio and higher upside potential. Analysts favor IRIDEX due to its lower beta and higher probable upside.Stock TitanIridex sets Q3 2026 earnings date for Nov. 17Iridex Corporation announced it will report third-quarter 2026 financial results after the close of trading on November 17, 2026. The company will also host a conference call at 2:00 p.m. PT, with dial-in and webcast details provided.GlobeNewswireIridex to Report Third Quarter 2026 Financial Results on November 17, 2026Iridex Corporation announced it will report third-quarter 2026 financial results and a business update after market close on November 17, 2026. The company will host a conference call at 2:00 p.m. PT, with dial-in and webcast details provided.